As Biosimilars Gain US Traction, Patent Thickets Are Under More Scrutiny
Sun Pharma announced a $12 billion acquisition of Organon to accelerate its entry into the global biosimilar market. The FDA has now approved roughly 90 biosimilars, which account for about 23 % of the U.S. biologics market, reflecting growing competition. Patent thickets—large clusters of patents around a single biologic, exemplified by Humira’s 100‑plus patents—have drawn regulatory scrutiny for delaying biosimilar launches. Recent FDA guidance lowers clinical data requirements, easing development costs and promising broader patient access despite ongoing litigation.
Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers
Radionuclide therapy, a precision cancer treatment delivering radioactive atoms directly to tumors, is gaining regulatory approvals and market traction. The class, anchored by early successes like Xofigo and the FDA‑approved Pluvicto, is projected to reach a $10.7 billion market by 2030....
China Now Holds 75% of Gene-Edited Seed Patents as Europe Moves to Loosen NGT Rules
China now commands roughly three‑quarters of all gene‑edited seed patents, with 16,177 filings in 2024—five times the EU total. The European Union is moving to loosen its New Genomic Techniques (NGT) rules, introducing a flexible NGT 1 category that avoids the...
GSK Eyes October FDA Verdict on Chronic Hep B Drug
GlaxoSmithKline’s antisense drug bepirovirsen entered an accelerated FDA review, with a decision expected by October 26. The phase‑2 B‑WELL 1 and B‑WELL 2 trials showed a statistically higher functional cure rate versus placebo when added to standard hepatitis B therapy. If approved, bepirovirsen would...
Building the Future of Biotechnology — UK Biotech Day 2026
UK Biotech Day 2026 will take place on May 27‑28 at the Radisson Hotel near Heathrow, bringing together industry leaders, researchers, government officials, and investors. The two‑day event highlights the UK’s rapid biotech growth, showcasing therapeutic innovation, manufacturing advances, health‑tech...
Novartis’ Sales Dip as Generics Pressure Intensifies, Radioequivalents Loom
Novartias first‑quarter net sales slipped 5% to $13.11 billion, primarily due to U.S. generic erosion of its heart‑failure drug Entresto. While earnings per share fell 11% to $1.65, growth was buoyed by double‑digit gains in Kisqali, Kesimpta and the radiopharma Pluvicto....
Revolution Levels Legal Threat on Erasca as Pancreatic Cancer Rivalry Heats Up
Revolution Medicines, after its Phase 3 pancreatic cancer drug daroxinrasib showed a median overall survival of 13.2 months and lifted its share price, sent a cease‑and‑desist letter to rival Erasca demanding the U.S. halt of ERAS‑0015, alleging patent infringement and misleading...
University of Colorado Boulder Finds Brain Circuit That May Flip Acute Pain Into Chronic Pain
Scientists at the University of Colorado Boulder have pinpointed a tiny brain region, the caudal granular insular cortex, that appears to decide whether short‑term pain becomes chronic. The discovery could reshape how meditation and other mind‑based interventions target persistent pain.
PapB Enzyme Enhances Ozempic; Endoscopic Procedure Cuts GLP‑1 Weight Rebound
Scientists at the University of Utah introduced PapB, an enzyme that macro‑cyclizes GLP‑1 peptides, potentially extending Ozempic’s efficacy. At the same time, a European‑based endoscopic duodenal mucosal resurfacing (DMR) trial demonstrated that patients maintained more than 80% of their weight...
AstraZeneca's Dual Immunotherapy Approved in China for Advanced Liver Cancer
AstraZeneca announced that China's National Medical Products Administration has approved tremelimumab (Imjudo) plus durvalumab (Imfinzi) for first‑line treatment of advanced or unresectable hepatocellular carcinoma (HCC). The decision is based on the global Phase III HIMALAYA trial and a supportive Chinese cohort...
Targeting Senescent Cells as a Treatment for Chronic Obstructive Pulmonary Disease
Researchers have introduced BCLXL-PROTAC, a proteolysis‑targeting chimera that degrades the anti‑apoptotic protein BCLXL in senescent lung cells. In primary small‑airway epithelial cells and fibroblasts from COPD patients, the compound induced caspase‑3‑mediated apoptosis and lowered classic senescence markers such as p21,...
Senescent Macrophages Are Important in Liver Aging and Liver Disease
Researchers identified a distinct p21‑positive, TREM2‑positive senescent macrophage population that accumulates in aging and fatty livers. These cells drive chronic inflammation through a senescence‑associated secretory phenotype linked to type I interferon signaling. In mouse models, senolytic agents that selectively eliminate these...
Novartis Q1 Profit Falls to $3.16 Billion as Generic Competition Erodes Sales
Novartis AG posted a first‑quarter profit of $3.156 billion, down from $3.609 billion a year earlier, and revenue slipped 0.9% to $13.113 billion. The results missed analysts’ forecasts, reflecting pressure from generic rivals on several flagship drugs.
AI-Powered Longevity Science — One Gene to Reverse Aging? | Daniel Ives PhD
In this episode, Dr. Robert Lovekin talks with Dr. Daniel Ives, founder of Shift Bioscience, about moving from hypothesis‑driven aging research to data‑driven, AI‑powered approaches. Ives explains how his early focus on mitochondrial DNA mutations as the primary cause of...
How Wireless Tags Can Help Monitor Your Breathing
Researchers from Chalmers University of Technology, Sahlgrenska University Hospital and the University of Gothenburg have demonstrated a contactless method for monitoring breathing using plaster‑like RFID tags. In a proof‑of‑concept test on a mannequin, the tags captured subtle chest‑wall movements and...
How to Get Pfizer & Moderna mRNA Out of Your Body
The article explains that Pfizer‑BioNTech and Moderna COVID‑19 vaccines rely on lipid‑nanoparticle‑encapsulated synthetic mRNA that is chemically altered with N1‑methylpseudouridine. This modification cloaks the RNA from innate immune sensors and dramatically slows enzymatic breakdown, extending its intracellular lifespan. Consequently, the...
We May Finally Have a Cure for Many Different Autoimmune Conditions
A novel cancer immunotherapy is being repurposed to eliminate rogue T‑cells that drive autoimmune diseases. Early trials show it can eradicate the pathogenic cells rather than merely suppressing symptoms, delivering faster and more durable remission. Dozens of global studies are...
Symptom-Based Approach Treats Opioid Withdrawal in Newborns with Minimal Drug Exposure
An NIH‑funded OPTimize NOW trial compared symptom‑based, as‑needed opioid dosing with traditional scheduled tapering for newborns with moderate to severe neonatal opioid withdrawal syndrome (NOWS). Among 383 infants cared for under the family‑centered Eat‑Sleep‑Console model, the symptom‑based group was ready for...
Oruka Reports Positive Data From Phase IIa Trial for Plaque Psoriasis
Oruka Therapeutics announced interim results from its EVERLAST‑A Phase IIa trial of ORKA‑001, a half‑life‑extended IL‑23p19 monoclonal antibody, in moderate‑to‑severe plaque psoriasis. Of the 63 patients receiving the 600 mg dose, 63.5% achieved PASI 100 by week 16, meeting the primary endpoint, with 83%...
An Octopus Probe for High-Performance >1,300 Nm NIR-II Fluorescence Molecular Imaging of Cancer
Researchers at Stanford introduced the Octopus (OCTP) probe, a modular NIR‑II fluorescence agent that emits beyond 1,300 nm and targets the folate receptor. In pre‑clinical mouse studies, OCTP delivered markedly higher tumor‑to‑background ratios and brighter tumor signals than the FDA‑approved Cytalux...
Enhanced Mechanical Strength and Controlled Degradation of PLA/ZnO Nanoparticle Composites for Biodegradable Implants
Researchers have engineered polylactic acid (PLA) composites reinforced with zinc oxide (ZnO) nanoparticles in two morphologies—nanospheres and nanorods—to create biodegradable implant materials. Tensile testing revealed that PLA/ZnO nanosphere composites reach 25.20 MPa, outperforming the nanorod variant at 22.98 MPa. Incorporating ZnO accelerated...
Vitamin D Boosts Breast Cancer Treatment Success by 79%
Researchers at São Paulo State University conducted a randomized trial of 80 women over 45 undergoing neoadjuvant chemotherapy for breast cancer. One half received 2,000 IU of vitamin D daily, while the other took a placebo. After six months, 43% of the...
TB‑500 Is Not TB‑4: No Human Evidence
TB - 500 is a short chain fragment synthesized from Thymosin Beta-4. TB-4 has solid human evidence for use. TB500 has absolutely no evidence. Totally different compounds. They cannot be referred to interchangeably because they simply are NOT the same
FDA Clears Tandem’s Control‑IQ+ Closed‑Loop System for Pregnant Women with Type 1 Diabetes
The U.S. Food and Drug Administration approved Tandem Diabetes Care’s Control‑IQ+ automated insulin delivery system for use by pregnant women with type 1 diabetes, marking the first clearance of its kind. The decision follows the CIRCUIT trial, which showed a 12.6‑percentage‑point...
Intellia Files FDA BLA After Phase 3 Shows 87% Cut in HAE Attacks
Intellia Therapeutics announced a rolling biologics license application to the FDA after its Phase 3 HAELO trial demonstrated an 87% reduction in hereditary angioedema attacks with a single dose of lonvo‑z. The results, the first from an in‑vivo CRISPR therapy, could...
Janux Therapeutics Halts Development of EGFR‑Targeted TRACTr Candidate JANX008
Janux Therapeutics announced it will cease clinical development of JANX008, its EGFR‑targeted Tumor‑Activated T Cell Engager, after completing Phase 1a. The company said the data did not meet predefined activity thresholds, prompting a reallocation of resources to other TRACTr pipeline assets....
Breakthrough Prize Showcases Baby Gene‑Editing Miracle
The 2026 Breakthrough Prize ceremony (“the Oscars for science”) celebrated the achievements of many remarkable scientists and their students and collaborators last weekend. Here’s the video of the show: https://t.co/eCHUnDqrYX. And here’s the segment in which Anne Hathaway and Alex...
Balanced Longevity Research Shows Real Human Impact
Longevity Science Is Overhyped. But This Research Really Could Change Humanity. We were delighted to have @susandominus with us at the last academy meeting earlier this year. She does gives a balanced take on the latest rejuvenation science. This...
FDA Grants Breakthrough Therapy Designation to TERN-701 for Relapsed Ph+ CML
The FDA has awarded breakthrough therapy designation to TERN-701, Terns Pharmaceuticals’ oral BCR::ABL1 inhibitor, for adults with Philadelphia chromosome‑positive chronic myeloid leukemia who have failed at least two prior tyrosine kinase inhibitors. The decision follows phase 1/2 CARDINAL data showing...
Fluorescent Quail Embryos Could Help Solve Serious Birth Defects in Humans
Researchers have engineered a fluorescent quail embryo that lights up cells during the first 72 hours of development, allowing live, high‑resolution imaging of neural tube formation. Using confocal microscopy, they tracked individual cell movements and discovered that loss of the...
10x Genomics Unveils A
I've been watching spatial biology for years. What @10xGenomics just announced changes the game. Serge Saxonov, CEO and Co-founder, 10x Genomics told Synbiobeta, "Biology is inherently complex, and as much progress as we have made, we still understand only a...
Low‑cost Vaccines Delivered, Autism Genes
What a dishonest & ignorant thing to write, I develop low-cost vaccines for global health, 100 million doses administered, without patenting the technology. Also as I’ve detailed we’ve learned a lot about the genetic basis of autism, >100 autism genes,...
Merck Beats EPS Forecast but Revenue Misses, Shares Slide 3.7% Pre‑Market
Merck & Co. reported Q2 2025 earnings that topped expectations on earnings per share, delivering $2.13 versus the $2.03 consensus. Revenue, however, slipped to $15.8 billion, missing the $15.87 billion outlook and prompting a 3.67% drop in the stock during pre‑market trading....
AstraZeneca's Bretzi Inhaler Cleared for Asthma in Teens
#AZN Bretzi inhaler approved by US FDA for treating patients 12 years old and upwards for Asthma, following the KALOS and LOGOS Phase III trials. Previously got COPD approval.
Morgan Stanley Flags IL‑23 Combos, Seeks Novel MOAs
Immunology combination studies from Morgan Stanley ahead of DUET data next week. These are mainly coformulations of established drugs, it would be more intriguing to see novel MOAs added to an IL23 backbone. https://t.co/dde8MpBhUR
Asgard Therapeutics to Unveil AT‑108 Gene Therapy Data at ASGCT 2026
Asgard Therapeutics announced that it will present advanced preclinical data on AT‑108, its first‑in‑class off‑the‑shelf gene‑based cancer immunotherapy, at the ASGCT Annual Meeting in Boston (May 11‑15, 2026). The study shows systemic anti‑tumor immunity, an abscopal effect, and identifies dosing...
Enhanced Exosomes Modulate OA Inflammatory Microenvironment
The role of exosomes and their enhancement strategies in the treatment of osteoarthritis "This article provides a comprehensive review and update on the research of exosomes, a type of extracellular vesicle, in the treatment of OA by modulating the inflammatory microenvironment..." https://t.co/xHjTCixJNE
Traditional MDs Now Seeking Peptide Knowledge for Joint Health
So many of my “conventional” (not in the health and wellness space or even online much) MD friends are asking about peptides to 1) get educated (patients are asking them about peptides) 2) they want to know if BPC can help their...
How Big Is Organon’s Biosimilar Push for Sun Pharma?
Sun Pharma’s $11.75 billion acquisition of Organon propels the Indian drugmaker into the global biosimilars market, placing it among the top ten players. Organon’s biosimilar portfolio generated $691 million in 2025, about 11 % of its total revenue, with 45 % of that coming...
Drugging the Undruggable: Cancer's Slipperiest Targets Finally Meet Their Match
Researchers at the University of British Columbia and BC Cancer have unveiled a novel drug design strategy that tightly binds intrinsically disordered proteins, long deemed undruggable. The new compounds exhibit binding affinities up to a million times stronger than previous...
Bacteria-Resistant Coating on Catheters Reduces Infection and Need for Antibiotics
A clinical trial of Camstent's bacteria‑resistant polymer‑coated catheter showed a one‑third drop in catheter‑associated urinary tract infections (CAUTIs) and more than a 50 % reduction in antibiotic use versus standard catheters. Long‑term patients using the coated device reported zero symptomatic CAUTIs...
Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Transcript
Nautilus Biotechnology reported a 23% drop in Q1 operating expenses to $15.4 million and ended the quarter with $156.1 million in cash, extending its runway into 2027. Management guided to modest $0.5 million revenue in 2026, primarily from grant‑funded early access customers, while...
From Trial‑and‑Error to Predictive Cell‑Fate Engineering
We’re still engineering biology by trial and error. SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ18mc @MichaBreakstone is building a model to predict cell fate with his new...
CDER Proposes to Withdraw Approval of TAVNEOS
The FDA’s Center for Drug Evaluation and Research has proposed withdrawing approval of TAVNEOS (avacopan) after uncovering data manipulation in the pivotal trial and a lack of demonstrated efficacy for severe ANCA‑associated vasculitis. The agency also flagged new safety signals,...
Lithium Interaction Poses Major Seizure Risk with Psilocybin
Most physicians were never taught psilocybin in medical school. Their patients in three states can now legally access it. Oregon's program has been operating since summer 2023. Colorado's healing centers came online in 2025. New Mexico passed its Medical Psilocybin...
Autologous iPSC Dopamine Cells Boost Parkinson’s Function without Immunosuppression
I’ve been following @jeannefrances's work for years, and what @AspenNeuro just reported out of Copenhagen is the kind of result that changes a field. Twelve months after receiving their own reprogrammed dopamine neurons, eight Parkinson's patients are showing real, measurable...
China Races to Build Record Biobank to Rival US Drugs Research
China is constructing a national biobank that will house blood and DNA samples from 33,000 children, targeting brain‑disease research. The initiative, led by the Chinese Institute for Brain Research, seeks to create a data‑rich platform that rivals the United States’...
Elliot Hershberg Returns to Lead AI Protein Dynamics Session
Why has @ElliotHershberg been coming to @SynBioBeta for the past 4 years in a row?? Elliot is a Partner at @AmplifyPartners and one of the sharpest minds at the intersection of biology and capital. He'll be moderating one of the...
Cellular Rejuvenation Could Shift Medicine to Youthful Resilience
Cellular rejuvenation may redefine medicine—not by treating disease, but by restoring youthful resilience at the cellular level. But science, safety, and hype are colliding. Worth the read (gift link) : 👇 https://t.co/7JGNdhFsFP via @NYTimes
The BioPharm Brief: FDA Advances Autoimmune Pipeline with New Delivery Options and Priority Review
The FDA cleared a subcutaneous autoinjector for anifrolumab, allowing at‑home treatment of moderate‑to‑severe systemic lupus erythematosus. It also granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia, a rare blood disorder, accelerating its path to market. AbbVie submitted a...